These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 11290537)
21. Epstein-Barr virus infection is associated with increased apoptosis in untreated and phorbol ester-treated human Burkitt's lymphoma (AW-Ramos) cells. Ishii HH; Gobé GC Biochem Biophys Res Commun; 1993 May; 192(3):1415-23. PubMed ID: 8389551 [TBL] [Abstract][Full Text] [Related]
22. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder. Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034 [TBL] [Abstract][Full Text] [Related]
23. Activation of p53 by MDM2 antagonists has differential apoptotic effects on Epstein-Barr virus (EBV)-positive and EBV-negative Burkitt's lymphoma cells. Renouf B; Hollville E; Pujals A; Tétaud C; Garibal J; Wiels J Leukemia; 2009 Sep; 23(9):1557-63. PubMed ID: 19421231 [TBL] [Abstract][Full Text] [Related]
24. Resveratrol inhibits proliferation and survival of Epstein Barr virus-infected Burkitt's lymphoma cells depending on viral latency program. De Leo A; Arena G; Stecca C; Raciti M; Mattia E Mol Cancer Res; 2011 Oct; 9(10):1346-55. PubMed ID: 21856773 [TBL] [Abstract][Full Text] [Related]
25. [Clinical study of 40 children with Burkitt's and Burkitt-like lymphoma]. Zhang YH; Duan YL; Yang J; Jin L; Zhou CJ; Gao ZF Zhonghua Er Ke Za Zhi; 2008 Mar; 46(3):209-14. PubMed ID: 19099711 [TBL] [Abstract][Full Text] [Related]
26. Role of bcl-2 in Epstein-Barr virus-induced malignant conversion of Burkitt's lymphoma cell line Akata. Komano J; Takada K J Virol; 2001 Feb; 75(3):1561-4. PubMed ID: 11152530 [TBL] [Abstract][Full Text] [Related]
27. Synthesis, Antiproliferative and Pro-Apoptotic Effects of Nitrostyrenes and Related Compounds in Burkitt's Lymphoma. Byrne AJ; Bright SA; Fayne D; McKeown JP; McCabe T; Twamley B; Williams C; Meegan MJ Med Chem; 2018 Feb; 14(2):181-199. PubMed ID: 28969575 [TBL] [Abstract][Full Text] [Related]
28. Is endemic Burkitt's lymphoma an alliance between three infections and a tumour promoter? van den Bosch CA Lancet Oncol; 2004 Dec; 5(12):738-46. PubMed ID: 15581545 [TBL] [Abstract][Full Text] [Related]
29. Burkitt's lymphoma cell line bearing surface IgA and negative for nuclear antigen of Epstein-Barr virus (EBNA). Hayashi Y; Matsumura Y; Nishihira T; Watanabe I; Ohi R; Kasai M; Kumagai K; Kamada N Jpn J Exp Med; 1980 Dec; 50(6):423-34. PubMed ID: 6268866 [TBL] [Abstract][Full Text] [Related]
30. Latent membrane protein-1 induces cyclin D2 expression, pRb hyperphosphorylation, and loss of TGF-beta 1-mediated growth inhibition in EBV-positive B cells. Arvanitakis L; Yaseen N; Sharma S J Immunol; 1995 Aug; 155(3):1047-56. PubMed ID: 7636179 [TBL] [Abstract][Full Text] [Related]
31. Potential mechanism of resistance to TRAIL-induced apoptosis in Burkitt's lymphoma. Tafuku S; Matsuda T; Kawakami H; Tomita M; Yagita H; Mori N Eur J Haematol; 2006 Jan; 76(1):64-74. PubMed ID: 16343273 [TBL] [Abstract][Full Text] [Related]
33. Sensitivity to dexamethasone and absence of bcl-2 protein in Burkitt's lymphoma cell line (Black93) derived from a patient with acute tumor lysis syndrome: comparative study with other BL and non-BL lines. Tani A; Tatsumi E; Nakamura F; Kumagai S; Kosaka Y; Sano K; Nakamura H; Amakawa R; Ohno H Leukemia; 1996 Oct; 10(10):1592-603. PubMed ID: 8847894 [TBL] [Abstract][Full Text] [Related]
34. Human B-lymphoid cell lines. Nilsson K Hum Cell; 1992 Mar; 5(1):25-41. PubMed ID: 1329931 [TBL] [Abstract][Full Text] [Related]
35. Isolation of the human interleukin 10 promoter. Characterization of the promoter activity in Burkitt's lymphoma cell lines. Kube D; Platzer C; von Knethen A; Straub H; Bohlen H; Hafner M; Tesch H Cytokine; 1995 Jan; 7(1):1-7. PubMed ID: 7749063 [TBL] [Abstract][Full Text] [Related]
36. A hexameric phosphorothioate oligonucleotide telomerase inhibitor arrests growth of Burkitt's lymphoma cells in vitro and in vivo. Mata JE; Joshi SS; Palen B; Pirruccello SJ; Jackson JD; Elias N; Page TJ; Medlin KL; Iversen PL Toxicol Appl Pharmacol; 1997 May; 144(1):189-97. PubMed ID: 9169084 [TBL] [Abstract][Full Text] [Related]
37. Cationic lipids reduce time and dose of c-myc antisense oligodeoxynucleotides required to specifically inhibit Burkitt's lymphoma cell growth. Williams SA; Chang L; Buzby JS; Suen Y; Cairo MS Leukemia; 1996 Dec; 10(12):1980-9. PubMed ID: 8946941 [TBL] [Abstract][Full Text] [Related]
38. Artesunate activates the ATF4-CHOP-CHAC1 pathway and affects ferroptosis in Burkitt's Lymphoma. Wang N; Zeng GZ; Yin JL; Bian ZX Biochem Biophys Res Commun; 2019 Nov; 519(3):533-539. PubMed ID: 31537387 [TBL] [Abstract][Full Text] [Related]
39. Antiproliferative function of p27kip1 is frequently inhibited in highly malignant Burkitt's lymphoma cells. Barnouin K; Fredersdorf S; Eddaoudi A; Mittnacht S; Pan LX; Du MQ; Lu X Oncogene; 1999 Nov; 18(46):6388-97. PubMed ID: 10597239 [TBL] [Abstract][Full Text] [Related]
40. High susceptibility of an Epstein-Barr virus-converted Burkitt's lymphoma cell line to cytotoxic drugs. Okano M Leuk Res; 1997 May; 21(5):469-71. PubMed ID: 9225077 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]